Corpus overview


MeSH Disease

COVID-19 (13)

Fever (13)

Disease (13)

Cough (7)

Fatigue (6)


    displaying 1 - 10 records in total 13
    records per page

    On Modeling of COVID-19 MESHD for the Indian Subcontinent using Polynomial and Supervised Learning Regression MESHD

    Authors: Dishita Neve; Honey Patel; Harsh S Dhiman; Victoria Acquaye; Alfred D. Dai-Kosi; Alejandro J Krolewiecki; Juan P Aparicio; Haifeng Wang; Dejing Dou; Pete Bond; Paul Anthony McAry; Sharad Bhagat; Itti Munshi; Swapneil Parikh; Sachee Agrawal; Chandrakant Pawar; Mala Kaneria; Smita Mahale; Jayanthi Shastri; Vainav Patel; Paul Dark; Alexander Mathioudakis; Kathryn Gray; Graham Lord; Timothy Felton; Chris Brightling; Ling-Pei Ho; - NIHR Respiratory TRC; - CIRCO; Karen Piper Hanley; Angela Simpson; John R Grainger; Tracy Hussell; Elizabeth R Mann

    doi:10.1101/2020.10.14.20212563 Date: 2020-10-16 Source: medRxiv

    COVID-19 MESHD, a recently declared pandemic by WHO has taken the world by storm causing catastrophic damage MESHD to human life. The novel cornonavirus disease MESHD was first incepted in the Wuhan city of China on 31st December 2019. The symptoms include fever HP fever MESHD, cough HP cough MESHD, fatigue MESHD fatigue HP, shortness of breath MESHD or breathing difficulties, and loss of smell and taste. Since the devastating phenomenon is essentially a time-series representation, accurate modeling may benefit in identifying the root cause and accelerate the diagnosis. In the current analysis, COVID-19 MESHD modeling is done for the Indian subcontinent based on the data collected for the total cases confirmed TRANS, daily recovered, daily deaths, total recovered and total deaths. The data is treated with total confirmed cases TRANS as the target variable and rest as feature variables. It is observed that Support vector regressions yields accurate results followed by Polynomial regression. Random forest regression results in overfitting followed by poor Bayesian regression due to highly correlated feature variables. Further, in order to examine the effect of neighbouring countries, Pearson correlation matrix is computed to identify geographic cause and effect.

    Symptoms associated with SARS-CoV-2 infection MESHD in a community-based population: Results from an epidemiological study

    Authors: Brian E Dixon; Kara Wools-Kaloustian; William F Fadel; Thoomas J Duszynski; Constantin Yiannoutsos; Paul K Halverson; Nir Menachemi; Ayo-Maria Olofinuka; Vetty Agala; John Nwolim Paul; Doris Nria; Chinenye Okafor; Ifeoma Ndekwu; Chikezie Opara; Chris Newsom

    doi:10.1101/2020.10.11.20210922 Date: 2020-10-14 Source: medRxiv

    Background: Studies examining symptoms of COVID-19 MESHD are primarily descriptive and measured among hospitalized individuals. Understanding symptoms of SARS-CoV-2 infection MESHD may improve clinical screening, particularly during flu season. We sought to identify key symptoms and symptom combinations in a community-based population. Methods: We pooled statewide, community-based cohorts of individuals aged TRANS 12 and older screened for SARS-CoV-2 infection MESHD in April and June 2020. Main outcome was SARS-CoV-2 positivity. We calculated sensitivity SERO, specificity, positive predictive value SERO (PPV), and negative predictive value SERO (NPV) for individual symptoms as well as symptom combinations. We further employed multivariable logistic regression and exploratory factor analysis (EFA) to examine symptoms and combinations associated with SARS-CoV-2 infection MESHD. Results: Among 8214 individuals screened, 368 individuals (4.5%) were RT-PCR positive for SARS-CoV-2. Although two-thirds of symptoms were highly specific (>90.0%), most symptoms individually possessed a PPV <50.0%. The individual symptoms most greatly associated with SARS-CoV-2 positivity were fever HP fever MESHD (OR=5.34, p<0.001), anosmia MESHD anosmia HP (OR=4.08, p<0.001), ageusia MESHD (OR=2.38, p=0.006), and cough HP (OR=2.86, p<0.001). Results from EFA identified two primary symptom clusters most associated with SARS-CoV-2 infection MESHD: (1) ageusia, anosmia HP anosmia MESHD, and fever MESHD fever HP; and (2) shortness of breath MESHD, cough HP, and chest pain HP chest pain MESHD. Moreover, being non-white (13.6% vs. 2.3%, p<0.001), Hispanic (27.9% vs. 2.5%, p<0.001), or living in an Urban area (5.4% vs. 3.8%, p<0.001) was associated with infection. Conclusions: When laboratory testing is not readily accessible, symptoms can help distinguish SARS-CoV-2 infection MESHD from other respiratory viruses. Symptoms should further be structured in clinical documentation to support identification of new cases and mitigation of disease MESHD disease spread TRANS by public health. These symptoms, derived from mildly infected individuals, can also inform vaccine and therapeutic clinical trials.

    The Impact of Colchicine on The COVID-19 MESHD Patients; A Clinical Trial Study

    Authors: Farhad Salehzadeh; Farhad Pourfarzi; Sobhan Ataei

    doi:10.21203/ Date: 2020-08-31 Source: ResearchSquare

    Background: Severe acute respiratory syndrome COVID-19 infection MESHD COVID-19 MESHD infection has evolved into a global pandemic. This study has been designed to evaluate colchicine anti-inflammatory effect on the symptoms course, duration of hospitalization, morbidity and mortality rate, of COVID-19 MESHD patients.Methods: In this prospective, open-label, randomized and double blind clinical trial, 100 patients hospitalized with COVID-19 MESHD were randomized in a 1:1 allocation from May 21 to June 20, 2020, to either standard medical treatment (Hydroxychloroquine) or colchicine with standard medical treatment. The study took place in Imam Reza hospital of Ardabil city in Iran, with trial registration ID: 47707 ( Colchicine group were received 1 mg tablet of colchicine daily alongside the Hydroxychloroquine for 6 days. Primary end points were (1) Length of hospitalization; (2) symptoms and (3) Co-existed disease. Secondary end points were examined 2 weeks after discharge and included (1) mortality and morbidity; (2) re-admission and (3) symptoms. Results: Overall, 100 patients (59 [59%] female TRANS; median age TRANS, 56 years) fulfilled the admission criteria and were included and randomized at 2 clinical groups. There was no significant difference between the two groups in terms of age TRANS and sex. Two groups were not significantly different in terms of underlying diseases MESHD and various clinical and para clinical findings although there were not any different during Post-discharge follow-up except for duration of fever HP fever MESHD (P<0.05). Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea HP dyspnea MESHD was improved more rapid than the placebo group, but it was not meaningful. Conclusion: Colchicine can be effective in reducing systemic symptoms of COVID-19 MESHD by inhibiting inflammatory biomarkers.Current Controlled prospective Trials registration ID that has been approved by ICMJE and WHO ICTRP registry is IRCT20200418047126N1, and the date of registration is 2020-05-14.

    Artificial Intelligence Based Study on Analyzing of Habits and with History of Diseases MESHD of Patients for Prediction of Recurrence of Disease Due to COVID-19 MESHD

    Authors: Samir Kumar Bandyopadhyay; Shawni Dutta

    id:10.20944/preprints202008.0542.v1 Date: 2020-08-25 Source:

    A patient will visit physicians when he/she feels ill. This illness is not for COVID-19 MESHD but it is a general tendency of human being to visit doctor probably it can not be controlled by general drug. When a patient comes to a doctor, the doctor examines him/her after knowing his/her problem. The physician always asks him/her about some questions related to him/her daily life. For example, if a young male TRANS patient comes to a doctor with a symptom of fever HP fever MESHD and cough HP cough MESHD, the first question doctor asked him that he has a habit of smoking. Then doctor asks him whether this type of symptom appeared often to him previously or not. If the answers of both questions are yes, then the first one is habit and the second one is that he may suffering from some serious disease MESHD or a disease due to the weather. The aim of this paper is to consider habit of the patient as well as he/she has been affected by a critical disease. This information is used to build a model that will predict whether there is any possibility of his/her being affected by COVID-19 MESHD. This research work contributes to tackle the pandemic situation occurred due to Corona Virus Infectious Disease MESHD, 2019 ( Covid-19 MESHD). Outbreak of this disease happens based on numerous factors such as past health records and habits of patients. Health records include diabetes tendency MESHD, cardiovascular disease MESHD existence, pregnancy, asthma MESHD asthma HP, hypertension MESHD hypertension HP, pneumonia HP pneumonia MESHD; chronic renal disease MESHD may contribute to this disease occurrence. Past lifestyles such as tobacco, alcohol consumption may be analyzed. A deep learning based framework is investigated to verify the relationship between past health records, habits of patients and covid-19 MESHD occurrence. A stacked Gated Recurrent Unit (GRU) based model is proposed in this paper that identifies whether a patient can be infected by this disease or not. The proposed predictive system is compared against existing benchmark Machine Learning classifiers such as Support Vector Machine (SVM) and Decision Tree (DT).

    Early clinical characteristics of Covid-19 MESHD: scoping review

    Authors: Lakshmi Manoharan; Jonathan W S Cattrall; Carlyn Harris; Katherine Newell; Blake Thomson; Mark G Pritchard; Peter G Bannister; Louise Sigfrid; Tom Solomon; Peter W Horby; Gail Carson; Piero L Olliaro

    doi:10.1101/2020.07.31.20165738 Date: 2020-08-04 Source: medRxiv

    ABSTRACT Background: The Coronavirus disease 2019 MESHD ( covid-19 MESHD) pandemic has spread rapidly across the globe. Accurate clinical characterisation studies are essential to informing research, diagnosis and clinical management efforts, particularly early in a pandemic. In this scoping review we identify the clinical characteristics of patients admitted to hospital in the early months of the pandemic, focusing on symptoms, laboratory and imaging findings, and clinical outcomes. Methods: A scoping review. MEDLINE, EMBASE and Global Health databases were searched studies published from January 1st 2020 to April 28th 2020. Studies which reported on at least 100 hospitalised patients with covid-19 MESHD of any age TRANS were included. Results: Of 1,249 studies identified through the search 78 studies were eligible for inclusion; one randomized control trial and 77 observational studies presenting data on 77,443 patients admitted with covid-19 MESHD. Most studies were conducted in China (82%), 9% in the US and 10% in Europe and two studies were set in more than one country. No studies included patients from low and middle income countries. Coagulopathy MESHD was underrecognised as a complication in the early months of the pandemic. Use of corticosteroids varied widely, and the use of anticoagulants was reported in only one study. Fever HP Fever MESHD, cough and dyspnoea MESHD cough and dyspnoea HP are less common in older adults TRANS; gastrointestinal symptoms, as the only presenting feature may be underrecognised. The most common laboratory finding was lymphocytopenia MESHD. Inflammatory biomarkers were commonly elevated, including C-reactive protein and interleukin-6. Typical computed tomography findings include bilateral infiltrates however imaging may be normal in early disease. Data on clinical characteristics in children TRANS and vulnerable populations were limited. Conclusions: Clinical characterisation studies from early in the pandemic indicated that covid-19 MESHD is a multisystem disease MESHD, with biomarkers indicating inflammation MESHD and coagulopathy MESHD. However, early data collection on symptoms and clinical outcomes did not consistently reflect this wide spectrum. Corticosteroid use varied widely, and anticoagulants were rarely used. Clinicians should remain vigilant to the possibility of covid-19 MESHD in patients presenting without fever HP fever MESHD, cough and dyspnoea MESHD cough and dyspnoea HP, particularly in older adults TRANS. Further characterisation studies in different at-risk populations is needed. Review registration: Available at Keywords: Covid-19 MESHD, clinical characteristics, symptoms, biochemical parameters, imaging, outcomes, pandemic research

    Clinical Characteristics of COVID-19 MESHD and the Value of Mulbsta Scoring System in Prognosis Evaluation

    Authors: Chao Wang; Zhixiu Luo; Junyi Wu; Jie Zhou; Yahang Lin; Guilin Yan; Manman Yan; Xi Wang; Hanhua Yu; Xiaoyun Zeng

    doi:10.21203/ Date: 2020-06-14 Source: ResearchSquare

    Background COVID-19 MESHD, a worldwideinfectious disease MESHD, has killed more than 420000 people, whichis extremely harmful.MethodsIn this single-center retrospective study, we included the novel coronavirus pneumonia MESHD pneumonia HP confirmed in our hospital. This study collected the basic information andclinical examination features.ResultsThe enrolled 704 patients were affirmed infected with 2019-nCoV by the test of throat swabs. There are 334 men and 369 women, and gender TRANS, age TRANS, combined with basic diseasesare distinct in diverse disease classification (p<0.05). From the symptom analysis, the proportion of fever HP fever MESHD over 38 degrees, dyspnea HP dyspnea MESHD, fatigue MESHD fatigue HP, poor appetite HP and other symptoms is diverse in different types of diseases (p<0.05). As the severity of the disease increases, the median lymphocyte count decreases, C-reactive protein increase, erythrocyte sedimentation rateincrease, albumin decrease, pleural effusion HP pleural effusion MESHD increase, D-Dimer and NT-proBNP increase significantly (p<0.05).As the disease severity increases, the average value of MuLBSTA score obviously ascend (p<0.05), MuLBSTA scoring system predicts novel coronavirus pneumonia MESHD pneumonia HP patients' prognosis is still insufficient, and may require additional indicators including anorexia HP anorexia MESHD, fatigue HP fatigue MESHD, C reactive protein, etc (p<0.05).ConclusionThe MuLBSTA evaluation system has certain value for the evaluation of the disease, but it needs to be improved.

    Early effect of SARS-COV-2 on renal tubule: a pilot study

    Authors: Mengyan Wang; Xiaotian Dong; Jun Yan; Zhongdong Zhang; Jinchuan Shi; Shourong Liu

    doi:10.21203/ Date: 2020-05-12 Source: ResearchSquare

    Objective: To explore the early clinical characteristics of coronavirus disease 2019 MESHD ( COVID-19 MESHD) and provide a reference for the early prevention and treatment of the disease.Methods: We collected and analyzed demographic data, medical history, exposure history, underline diseases MESHD, symptoms, signs, laboratory data, chest computed tomographic (CT) scans, and treatment measures of COVID-19 MESHD patients admitted to the Sixth People's Hospital of Hangzhou from January 20 to February 23, 2020.Results: Among 51 confirmed COVID-19 MESHD patients included in this study, 7.8% (4/51) patients were severe and 45.1% (23/51) were male TRANS. Median age TRANS was 43 years (IQR, 23). Fever HP Fever MESHD (54.9%, 28/51) and cough HP (52.9%, 27/51) were the main symptoms. 74.5% (38/51) patients had a history of exposure and 17.6% (9/51) patients had a history of hypertension HP hypertension MESHD. Importantly, most (60.8%, 31/51) patients had an increase of urine β2 microglobulin. In addition, the inflammation MESHD indexes (C-reactive protein and serum SERO amyloid A) of patients with elevated urine β2 microglobulin were significantly increased (p = 0.017 and p = 0.049) and lymphocytes count was significantly reduced (p = 0.012), compared with patients with normal urine β2 microglobulin. Correlation analysis showed that urine β2 microglobulin was positively correlated with C-reactive protein and serum SERO amyloid A; but negatively correlated with lymphocytes count.Conclusions: COVID-19 MESHD patients have obvious symptoms of lung injury MESHD, but the occurrence of early renal tubular injuries MESHD has to be monitored vigilantly.

    The first 2019-nCoV infection MESHD case report from Iran

    Authors: Maryam Mansoori; Somayeh Vafaei; Zahra Madjd; Masoume Mesgarian

    doi:10.21203/ Date: 2020-05-01 Source: ResearchSquare

    Background: The total mortality rate of COVID-19 MESHD is estimated almost at 2 % based on a wide range of publications. To avoid negative global impact of this new emergency, the entailment of control measures for prevention is highly recommended. Unfortunately, Iran has been the manifestation of attention as one of the countries is struggling with this pandemic. Here we intend to report a unique case of 2019-nCoV infected patient with underlying diseases MESHD and one of the rare pulmonary manifestations of 2019-nCoV infection MESHD ( pleural effusion HP pleural effusion MESHD) who has recovered and discharged. Case presentation: The current case report from Iran showed a positive COVID-19 MESHD case accompanied by pleural effusion HP pleural effusion MESHD and severe pneumonia HP pneumonia MESHD and even underlying diseases. She received twelve days of treatment and recovered with good oxygen saturation and without associated factors including fever MESHD fever HP and cough MESHD cough HP. In this report, presentations, diagnoses and management of novel 2019 coronavirus patient has been described in details. Conclusions: The pleural effusion HP pleural effusion MESHD in 2019-nCoV is not a dominant feature and can be considered as one of the diagnostic features in the disease. Even with underlying diseases, 2019-nCoV symptoms are not supposed to be severed. 

    Clinical Characteristics of 208 Patients with COVID-19 MESHD in a Surrounding City of Wuhan, China

    Authors: Xin Chen; Peng Chen; Dodji Kossi Djakpo; Yan Lin; Rong Zhang; Zhiquan Wang

    doi:10.21203/ Date: 2020-04-19 Source: ResearchSquare

    Background: Since December 2019, a severe novel coronavirus ( SARS-CoV-2) infection (Coronavirus Disease MESHD Coronavirus Disease 2019 MESHD, COVID-19 MESHD) has occurred in Wuhan, China, and has rapidly spread to the country and around the world. This study intends to investigate the epidemiological and clinical characteristics of patients with COVID-19 MESHD in a surrounding city of Wuhan.Methods: A retrospective study was conducted on 208 cases of COVID -19 patients from February 11, 2020 to February 29, 2020 in Xiaogan dongnan Hospital, collected basic information, history of exposure, medical history, clinical symptoms, laboratory indicators and pulmonary imaging Data, and analyzed the epidemiological and clinical characteristics of all patients. According to the clinical classification criteria, 208 patients were divided into light group and ordinary group, and the epidemiological and clinical characteristics of the two groups were compared.Results: Among 208 patients in this study, with a median age TRANS of 50.5 years (IQR,36-64.7,range,10-91 years), among which 107 (51.4%) were males TRANS and 101 (48.6%) were females TRANS. 51 (24.5%) had a clear exposure to COVID-19 MESHD infection within 2 weeks before admission, and 40 (19.2%) had a history of residence or exposure in Wuhan within 2 weeks before admission. Among all the patients, there were 16 (7.7%) with pulmonary diseases MESHD, 41 (19.7%) with hypertension HP hypertension MESHD, 11 (5.3%) with coronary heart disease MESHD, 13 (6.3%) with diabetes MESHD, 12(5.8%) with a history of alcohol consumption, and 12(5.8%) with a history of smoking. Among all clinical symptoms, 146 cases (70.2%) of fever HP fever MESHD, the highest temperature range was 37.3℃-41℃ before admission, 115 (55.3%) cases of cough HP, and 57 (27.4%) cases of chest tightness HP chest tightness MESHD, 47 (22.6%) cases of fatigue HP fatigue MESHD, 28 (13.5%) cases of inappetence, 9 (4.3%) cases of diarrhea HP diarrhea MESHD, 7 (3.4%) cases of nasal congestion or runny nose , and 5 ( 2.4%) cases of pharyngalgia. Analysis of the laboratory results of 208 patients showed that 42 (20.2%) cases had decreased white blood SERO cell count, and 61 (29.3%) cases had decreased lymphocyte count. There were 154 (74%) cases with elevated CRP, 50 (24%) cases with elevated fasting blood SERO glucose, and 23 (11.1%) cases with elevated LDH (>245U/L). The comparison of clinical characteristics between the light group and the common group showed that the median age TRANS of the light group was 44.8 years (IQR 30-58), the median age TRANS of the common group was 53.1 years (IQR 38.8-67) (P<0.01). The symptoms of fever MESHD fever HP [53(80.3%) vs 93(65.5%),P<0.05], fatigue HP fatigue MESHD [53(80.3%) vs 93(65.5%),P<0.05] and inappetence [4(6.1%) vs 24(16.9%),P<0.05] in the light group were less than those in the common group. The white blood SERO cell count (5.48 vs 6.37, P<0.05), lymphocyte count (1.40 vs 1.61, P<0.05) and HDL-C (1.5 vs 1.3, P<0.05) of the common group were lower than that of the light group, while CRP (26.5 vs 22.1, P<0.01), AST (22.9 vs 18.5, P<0.05), fasting blood SERO glucose (5.8 vs 5.6, P<0.05), LDH (196.8 vs 157.9, P<0.001) of the common group were higher than that of the light group.Conclusion: COVID-19 MESHD infection is mainly in middle- aged TRANS and elderly TRANS patients, patients with other diseases MESHD are more susceptible to infection. The main symptoms of COVID-19 MESHD infection were fever HP fever MESHD, cough MESHD cough HP, chest tightness MESHD chest tightness HP, fatigue HP fatigue MESHD, and inappetence. Decreased lymphocyte count, increased CRP concentration, increased LDH concentration and decreased HDL-C concentration were the laboratory features of COVID-19 MESHD infection, and were important indicators to assess the severity of COVID-19 MESHD disease.

    Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

    Authors: Ujjwal Neogi; Kyle J. Hill; Anoop T. Ambikan; Xiao Heng; Thomas P. Quinn; Siddappa N. Byrareddy; Anders Sönnerborg; Stefan G. Sarafianos; Kamal Singh

    id:10.20944/preprints202004.0184.v1 Date: 2020-04-12 Source:

    Coronaviruses (CoVs) are positive-stranded RNA viruses that infect MESHD humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKUI1 leads to the common cold, short lasting rhinitis MESHD rhinitis HP, cough HP, sore throat and fever MESHD fever HP. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) MESHD, and the newest SARS-CoV-2 (the causative agent of COVID-19 MESHD) lead to severe and deadly diseases MESHD with mortality rates ranging between ~1 to 35% depending on factors such as age TRANS and pre-existing conditions. Despite continuous global health threats to human, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 MESHD emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.